ArticleCurrent oncology (Toronto, Ont.)2021

Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells.

Ritu Shrestha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.